Rite Aid (RAD) Comps Fell 2% in March
Tweet
Share
E-mailGet Alerts RAD Hot Sheet
Join SI Premium – FREE
Rite Aid Corporation (NYSE: RAD) today announced sales results for March.
Monthly Sales
For the four weeks ended March 30, 2013, same store sales decreased 2.0 percent over the prior-year period. March front-end same store sales increased 3.8 percent, with 3.0 percent of the increase attributable to a shift in the timing of Easter, which fell on March 31 this year compared to April 8 last year. Pharmacy same store sales, which included an approximate 566 basis points negative impact from new generic introductions, decreased 4.5 percent. Prescription count at comparable stores increased 0.3 percent over the prior-year period.
Total drugstore sales for the four-week period decreased 2.5 percent to $1.939 billion compared to $1.989 billion for the same period last year. Prescription sales accounted for 67.6 percent of drugstore sales, and third party prescription sales represented 97.0 percent of pharmacy sales.
Monthly Sales
For the four weeks ended March 30, 2013, same store sales decreased 2.0 percent over the prior-year period. March front-end same store sales increased 3.8 percent, with 3.0 percent of the increase attributable to a shift in the timing of Easter, which fell on March 31 this year compared to April 8 last year. Pharmacy same store sales, which included an approximate 566 basis points negative impact from new generic introductions, decreased 4.5 percent. Prescription count at comparable stores increased 0.3 percent over the prior-year period.
Total drugstore sales for the four-week period decreased 2.5 percent to $1.939 billion compared to $1.989 billion for the same period last year. Prescription sales accounted for 67.6 percent of drugstore sales, and third party prescription sales represented 97.0 percent of pharmacy sales.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Radiopharm raises up to $13M via US and Australian offerings
- Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan
- Nir Brenmiller named CEO of Brenmiller Energy after shareholder vote
Create E-mail Alert Related Categories
Retail SalesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
